{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:11:01Z","timestamp":1793211061785,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017959","name":"Health Commission of Hebei Province","doi-asserted-by":"publisher","award":["20231222"],"award-info":[{"award-number":["20231222"]}],"id":[{"id":"10.13039\/100017959","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08014-3","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:57:08Z","timestamp":1773914228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A dual-mechanism model of Selinexor in DLBCL: p53 reactivation and metabolic reprogramming"],"prefix":"10.1186","volume":"24","author":[{"given":"Wenqi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuixin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanping","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoning","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boning","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"8014_CR1","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","volume":"16","author":"JO Armitage","year":"1998","unstructured":"Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin\u2019s lymphoma classification project. J Clin Oncol. 1998;16:2780\u201395.","journal-title":"J Clin Oncol"},{"key":"8014_CR2","first-page":"e70351","volume":"8","author":"M Aghaei","year":"2025","unstructured":"Aghaei M, JalaliFar MA, Yousefi-Avarvand A, Bahreiny SS, Karamali N, Mansouri Z, et al. Update Prognostic Potency of Vascular Endothelial Growth Factor-A in the Acute Lymphoblastic Leukemia Landscape: A Meta-Analysis. Cancer Rep (Hoboken). 2025;8:e70351.","journal-title":"Cancer Rep (Hoboken)"},{"key":"8014_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","volume":"11","author":"M Roschewski","year":"2014","unstructured":"Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11:12\u201323.","journal-title":"Nat Rev Clin Oncol"},{"key":"8014_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","volume":"7","author":"K Parikh","year":"2014","unstructured":"Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. J Hematol Oncol. 2014;7:78.","journal-title":"J Hematol Oncol"},{"key":"8014_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","volume":"83","author":"JG Turner","year":"2012","unstructured":"Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012;83:1021\u201332.","journal-title":"Biochem Pharmacol"},{"key":"8014_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/13543784.2020.1706087","volume":"29","author":"S Ben-Barouch","year":"2020","unstructured":"Ben-Barouch S, Kuruvilla J. Selinexor (KPT-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL). Expert Opin Investig Drugs. 2020;29:15\u201321.","journal-title":"Expert Opin Investig Drugs"},{"key":"8014_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13045-020-00982-3","volume":"13","author":"M Deng","year":"2020","unstructured":"Deng M, Zhang M, Xu-Monette ZY, Pham LV, Tzankov A, Visco C, Fang X, et al. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by Selinexor in the absence of mutant p53. J Hematol Oncol. 2020;13:148.","journal-title":"J Hematol Oncol"},{"key":"8014_CR8","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","volume":"7","author":"N Kalakonda","year":"2020","unstructured":"Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat J, Casasnovas O, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7:e511\u201322.","journal-title":"Lancet Haematol"},{"key":"8014_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11864-025-01295-8","volume":"26","author":"F Karimi","year":"2025","unstructured":"Karimi F, Aghaei M, Saki N. Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma. Curr Treat Options Oncol. 2025;26:197\u2013212.","journal-title":"Curr Treat Options Oncol"},{"key":"8014_CR10","doi-asserted-by":"crossref","unstructured":"Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009:1105\u201311.","DOI":"10.1093\/bioinformatics\/btp120"},{"key":"8014_CR11","doi-asserted-by":"crossref","unstructured":"Sun L, Luo H, Bu D, Zhao G, Yu K, Zhang C, Liu Y, et al. Utilizing sequence intrinsic composition to classify protein-coding and long non-coding transcripts. Nucleic Acids Res. 2013:e166.","DOI":"10.1093\/nar\/gkt646"},{"key":"8014_CR12","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1002\/imt2.36","volume":"3","author":"W Shen","year":"2022","unstructured":"Shen W, Zhang X, Zhang Z, et al. Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform. iMeta. 2022;3:e36.","journal-title":"iMeta"},{"key":"8014_CR13","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1002\/imt2.238","volume":"3","author":"D Chen","year":"2024","unstructured":"Chen D, Xu L, Xing H, Shen W, et al. Sangerbox 2: Enhanced functionalities and update for a comprehensive clinical bioinformatics data analysis platform. iMeta. 2024;3:e238.","journal-title":"iMeta"},{"key":"8014_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.21037\/atm-21-626","volume":"9","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Yuan J, Liu Y, Liu X, Lv T, Zhou K, Song Y. KIAA0101 knockdown inhibits cell proliferation and induces cell cycle arrest and cell apoptosis in chronic lymphocytic leukemia cells. Ann Transl Med. 2021;9:487.","journal-title":"Ann Transl Med"},{"key":"8014_CR15","doi-asserted-by":"publisher","first-page":"105943","DOI":"10.1016\/j.oraloncology.2022.105943","volume":"130","author":"S Jayaraman","year":"2022","unstructured":"Jayaraman S, Pazhani J, Priyaveeraraghavan V, Raj AT, Somasundaram DB, Patil S. PCNA and Ki-67: prognostic proliferation markers for oral cancer. Oral Oncol. 2022;130:105943.","journal-title":"Oral Oncol"},{"key":"8014_CR16","first-page":"4622","volume":"124","author":"PA Riedell","year":"2018","unstructured":"Riedell PA, Smith SM. Double hit and double expressors in lymphoma: definition and treatment. Cancer-Am Cancer Soc. 2018;124:4622\u201332.","journal-title":"Cancer-Am Cancer Soc"},{"key":"8014_CR17","doi-asserted-by":"crossref","unstructured":"Ehsan H, Robinson M, Voorhees PM, Cassetta K, Borden S, Atrash S, Bhutani M, Varga C, Pineda-Roman M, Friend R, Paul BA. Efficacy of Selinexor in relapsed\/refractory multiple myeloma (RRMM) patients with del17p and other high-risk abnormalities (a retrospective single-center study). Life (Basel). 2024;14.","DOI":"10.3390\/life14030384"},{"key":"8014_CR18","doi-asserted-by":"publisher","first-page":"30356","DOI":"10.1074\/jbc.M302902200","volume":"278","author":"M Monte","year":"2003","unstructured":"Monte M, Benetti R, Buscemi G, Sandy P, Del SG, Schneider C. The cell cycle-regulated protein human GTSE-1 controls DNA damage-induced apoptosis by affecting p53 function. J Biol Chem. 2003;278:30356\u201364.","journal-title":"J Biol Chem"},{"key":"8014_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/sj.onc.1200886","volume":"14","author":"Z Kelman","year":"1997","unstructured":"Kelman Z. PCNA: structure, functions and interactions. Oncogene. 1997;14:629\u201340.","journal-title":"Oncogene"},{"key":"8014_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s11033-024-10200-9","volume":"52","author":"L Rajabi","year":"2025","unstructured":"Rajabi L, Ebrahimdoost M, Mohammadi SA, et al. Aqueous and ethanolic extracts of Moringa oleifera leaves induce selective cytotoxicity in Raji and Jurkat cell lines by activating the P21 pathway independent of P53. Mol Biol Rep. 2025;52:102.","journal-title":"Mol Biol Rep"},{"key":"8014_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cmet.2019.11.020","volume":"31","author":"HC Yoo","year":"2020","unstructured":"Yoo HC, Park SJ, Nam M, Kang J, Kim K, Yeo JH, Kim JK, Heo Y, Lee HS, Lee MY, Lee CW, Kang JS, Kim YH, Lee J, Choi J, Hwang GS, Bang S, Han JM. A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells. Cell Metab. 2020;31:267\u201383.","journal-title":"Cell Metab"},{"key":"8014_CR22","first-page":"7451","volume":"15","author":"P Chen","year":"2023","unstructured":"Chen P, Jiang Y, Liang J, Cai J, Zhuo Y, Fan H, Yuan R, Cheng S, Zhang Y. SLC1A5 is a novel biomarker associated with ferroptosis and the tumor microenvironment: a pancancer analysis. Aging (Albany NY). 2023;15:7451\u201375.","journal-title":"Aging (Albany NY)"},{"key":"8014_CR23","doi-asserted-by":"crossref","unstructured":"Zhou Z, Song Q, Yang Y, Wang L, Wu Z. Comprehensive landscape of RRM2 with immune infiltration in pan-cancer. Cancers (Basel). 2022;14.","DOI":"10.3390\/cancers14122938"},{"key":"8014_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cytogfr.2018.02.001","volume":"40","author":"E Vicenzi","year":"2018","unstructured":"Vicenzi E, Poli G. The interferon-stimulated gene TRIM22: a double-edged sword in HIV-1 infection. Cytokine Growth Factor Rev. 2018;40:40\u20137.","journal-title":"Cytokine Growth Factor Rev"},{"key":"8014_CR25","doi-asserted-by":"crossref","unstructured":"Pagani I, Poli G, Vicenzi E. TRIM22. A multitasking antiviral factor. Cells-Basel. 2021;10.","DOI":"10.3390\/cells10081864"},{"key":"8014_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.molcel.2005.03.027","volume":"18","author":"RG Jones","year":"2005","unstructured":"Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005;18:283\u201393.","journal-title":"Mol Cell"},{"key":"8014_CR27","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/aps.2010.151","volume":"31","author":"XD Zhang","year":"2010","unstructured":"Zhang XD, Qin ZH, Wang J. The role of p53 in cell metabolism. Acta Pharmacol Sin. 2010;31:1208\u201312.","journal-title":"Acta Pharmacol Sin"},{"key":"8014_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cell.2008.06.028","volume":"134","author":"AV Budanov","year":"2008","unstructured":"Budanov AV, Karin M. P53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell. 2008;134:451\u201360.","journal-title":"Cell"},{"key":"8014_CR29","doi-asserted-by":"publisher","first-page":"775507","DOI":"10.3389\/fcell.2021.775507","volume":"9","author":"D Cui","year":"2021","unstructured":"Cui D, Qu R, Liu D, Xiong X, Liang T, Zhao Y. The cross talk between p53 and mTOR pathways in response to physiological and genotoxic stresses. Front Cell Dev Biol. 2021;9:775507.","journal-title":"Front Cell Dev Biol"},{"key":"8014_CR30","doi-asserted-by":"publisher","first-page":"103788","DOI":"10.1016\/j.redox.2025.103788","volume":"85","author":"J Cao","year":"2025","unstructured":"Cao J, Chen X, Chen L, Lu Y, Wu Y, Deng A, Pan F, Huang H, Liu Y, Li Y, Tong X, Du J. DHODH-mediated mitochondrial redox homeostasis: a novel ferroptosis regulator and promising therapeutic target. Redox Biol. 2025;85:103788.","journal-title":"Redox Biol"},{"key":"8014_CR31","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1007\/s00277-025-06387-x","volume":"104","author":"OS Aval","year":"2025","unstructured":"Aval OS, Ahmadi A, Al-Athari H. Galectin-9: A double-edged sword in Acute Myeloid Leukemia. Ann Hematol. 2025;104:3077\u201390.","journal-title":"Ann Hematol"},{"key":"8014_CR32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s10238-025-01751-7","volume":"1","author":"NS Sherafat","year":"2025","unstructured":"Sherafat NS, et al. Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective. Clin Experimental Med. 2025;1:238.","journal-title":"Clin Experimental Med"},{"key":"8014_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12964-024-01765-w","volume":"22","author":"KX Du","year":"2024","unstructured":"Du KX, Wu YF, Hua W, et al. Identify truly high-risk TP53-mutated diffuse large B cell lymphoma patients and explore the underlying biological mechanisms. Cell Commun Signal. 2024;22:401.","journal-title":"Cell Commun Signal"},{"key":"8014_CR34","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1007\/s00277-025-06410-1","volume":"104","author":"H Zhang","year":"2025","unstructured":"Zhang H, Zhang Z, Li L, et al. Genomic mutation profile and metabolic alterations in diffuse large B-cell lymphoma with abdominal bulky mass. Ann Hematol. 2025;104:3359\u201375.","journal-title":"Ann Hematol"},{"key":"8014_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41420-023-01475-1","volume":"9","author":"Y Cai","year":"2023","unstructured":"Cai Y, Lv L, Lu T, et al. \u03b1-KG inhibits tumor growth of diffuse large B-cell lymphoma by inducing ROS and TP53-mediated ferroptosis. Cell Death Discov. 2023;9:182.","journal-title":"Cell Death Discov"},{"key":"8014_CR36","doi-asserted-by":"publisher","first-page":"101658","DOI":"10.1016\/j.tranon.2023.101658","volume":"31","author":"YX Shi","year":"2023","unstructured":"Shi YX, Dai PH, Jiang YF, Wang YQ, Liu W. A pan-cancer landscape of centromere proteins in tumorigenesis and anticancer drug sensitivity. Transl Oncol. 2023;31:101658.","journal-title":"Transl Oncol"},{"key":"8014_CR37","doi-asserted-by":"crossref","unstructured":"Zhang H. Regulation of DNA replication licensing and re-replication by cdt1. Int J Mol Sci. 2021;22.","DOI":"10.3390\/ijms22105195"},{"key":"8014_CR38","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.21037\/tcr-22-491","volume":"11","author":"N Qi","year":"2022","unstructured":"Qi N, Niu Y, Li Z, Xiao L, Tang D, Gao W. The prognostic value and mechanisms of centromere protein m in patients with lung adenocarcinoma. Transl Cancer Res. 2022;11:3471\u201390.","journal-title":"Transl Cancer Res"},{"key":"8014_CR39","doi-asserted-by":"publisher","first-page":"648182","DOI":"10.3389\/fimmu.2021.648182","volume":"12","author":"L Sun","year":"2021","unstructured":"Sun L, Gang X, Li Z, Zhao X, Zhou T, Zhang S, Wang G. Advances in understanding the roles of CD244 (SLAMF4) in immune regulation and associated diseases. Front Immunol. 2021;12:648182.","journal-title":"Front Immunol"},{"key":"8014_CR40","doi-asserted-by":"crossref","unstructured":"Buller CW, Mathew PA, Mathew SO. Roles of NK cell receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in cancer. Cancers (Basel). 2020;12.","DOI":"10.3390\/cancers12071755"},{"key":"8014_CR41","doi-asserted-by":"crossref","unstructured":"Mohammed TO, Lin YR, Akter L, Weissenbruch K, Ngo KX, Zhang Y, Kodera N, Bastmeyer M, Miyanari Y, Taoka A, Franz CM. S100A11 promotes focal adhesion disassembly via myosin ii-driven contractility and piezo1-mediated Ca2\u2009+\u2009entry. J Cell Sci. 2024;137.","DOI":"10.1242\/jcs.261492"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08014-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08014-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08014-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:14:17Z","timestamp":1777353257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08014-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8014"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08014-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University (Approval No. 2025KY169). Written informed consent was obtained from all participants prior to their inclusion in the study. For participants under 18 years of age, consent was obtained from their legal guardians. For the cell line experiments, all procedures were conducted in accordance with institutional guidelines for laboratory research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed the final manuscript and consented to its publication. Written informed consent for publication of any potentially identifiable data was obtained from the study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"603"}}